administering a therapeutically effective amount of the compound in the carrier to an individual having said neurodegenerative disorder.

13. As a composition of matter, the compound obtained by the method of claim 11.

14. A pharmacologically acceptable composition comprising:

the compound obtained by the method of claim 11; and

a pharmaceutical carrier.

15. A method of screening for a compound for the treatment of a neurodegenerative disorder, comprising the steps of:

introducing a test compound into transfected cells in tissue culture, wherein said transfected cells produce protein aggregate; and

measuring the quantity of protein aggregate in said cells, wherein a test compound which decreases the quantity of protein aggregate as compared to control cells is considered the compound for the treatment of said neurodegenerative disorder.

16. The method of claim 15, further comprising:

dispersing the compound for the treatment of the neurodegenerative disorder in a pharmaceutical carrier; and

administering a therapeutically effective amount of the compound in the carrier to an individual having said neurodegenerative disorder.

17. As a composition of matter, the compound obtained by the method of claim

18. A pharmacologically acceptable composition comprising:

the compound obtained by the method of claim 15; and

a pharmaceutical carrier.

19. A method of treating a patient with a neurodegenerative disorder, comprising the steps of:

preparing a compound obtained by the method of claim 15; and

administering a therapeutically effective amount of said compound to said patient.

20. A method of screening for a compound which suppresses ataxin-1 aggregation comprising the steps of:

introducing a test compound into transfected cells in tissue culture, wherein said transfected cells produce protein aggregate; and

measuring the quantity of protein aggregate in said cells, wherein a test compound which decreases the quantity of protein aggregate as compared to control cells is considered the compound which suppresses ataxin-1 aggregation.

21. The method of claim 20, wherein method further comprises:

dispersing the compound which suppresses ataxin-1 aggregation in a pharmaceutical carrier; and

administering a therapeutically effective amount of the compound in the carrier to an individual having a neurodegenerative disorder.

22. As a composition of matter, the compound obtained by the method of claim 20.

23. A pharmacologically acceptable composition comprising:

the compound obtained by the method of claim 20; and

a pharmaceutical carrier.

24. A method of treating a patient with a neurodegenerative disorder, comprising the steps of:

preparing a therapeutically effective amount of a compound obtained by the method of claim 20; and

administering said therapeutically effective compound to said patient.